Compare Organon & Co. Common Stock (OGN) vs Star Bulk Carriers Corp (SBLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Star Bulk Carriers Corp — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Star Bulk Carriers Corp trades at $28.76 (market cap $3.46B). The key difference: Organon & Co. Common Stock and Star Bulk Carriers Corp are close in size by market cap, and Star Bulk Carriers Corp pays the higher dividend (6.31%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Star Bulk Carriers Corp for 23 Days on average.
| OGN | SBLK | |
|---|---|---|
Market Cap | $3.62B | $3.46B |
Volume | 2,892,999 | 1,078,337 |
Sector | Health | Industrials |
52-Week High | $13.81 | $32.49 |
52-Week Low | $5.70 | $17.42 |
Typical Hold Time | 0 Days | 23 Days |
Enterprise Value | $11.04B | $4.14B |
Dividend Yield | 0.58% | 6.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Star Bulk Carriers (SBLK) trades at $29.79, down 0.17% with a bearish technical signal despite strong fundamentals. The company demonstrates robust profitability with 23.87% net income margin and has beaten earnings estimates for three consecutive quarters. Recent insider buying activity and a 58.34% analyst buy rating signal confidence, while the stock offers an attractive valuation with P/E of 11.68 and upcoming $0.90 dividend payment.
SBLK presents a compelling value opportunity with strong earnings momentum and shareholder returns, though technical weakness and shipping sector volatility pose near-term risks. The company's 100% free cash flow distribution policy and projected revenue growth to $1.2B in 2026 support the bullish fundamental case, while bearish moving averages suggest potential consolidation before further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Star Bulk Carriers Corp
Star Bulk Carriers Corp. is a global shipping company specializing in the seaborne transportation of dry bulk commodities. The company owns and operates a large fleet of bulk carriers, primarily transporting major commodities such as iron ore, coal, and grain. SBLK focuses on the Capesize, Post Panamax, and Kamsarmax vessel segments, providing critical logistical services to commodity producers and consumers worldwide.
Read more on SBLK →
